Literature DB >> 2658896

Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis.

J W Chow1, V L Yu.   

Abstract

Staphylococcus aureus infections remain a major cause of morbidity in hemodialysis patients. Chronic dialysis patients are more prone to staphylococcal infections because of their decreased immunity, increased skin colonization by staphylococci, and the multiple needle punctures required for dialysis. The source of the staphylococci is the anterior nares. Elimination of staphylococcal nasal carriage results in a significantly lower infection rate. Selected clinical studies of topical and oral therapy for eradication of staphylococcal nasal carriage are reviewed. Rifampin has been the most consistently efficacious agent, although emergence of resistance is a potential problem. Trials utilizing newer topical and oral agents for prophylactic eradication of S aureus from the nose are indicated. Promising antibiotics include topical mupirocin, the oral quinolones, and clindamycin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658896

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  21 in total

Review 1.  Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks.

Authors:  J Kluytmans; A van Belkum; H Verbrugh
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Guidelines for the prevention of intravascular catheter-related infections.

Authors:  Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

3.  Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients.

Authors:  T Na'was; A Hawwari; E Hendrix; J Hebden; R Edelman; M Martin; W Campbell; R Naso; R Schwalbe; A I Fattom
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

Review 4.  Skin care: Historical and contemporary views.

Authors:  Khalid M AlGhamdi; Fahad A AlHomoudi; Huma Khurram
Journal:  Saudi Pharm J       Date:  2013-03-14       Impact factor: 4.330

5.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Authors:  T J Walsh; H C Standiford; A C Reboli; J F John; M E Mulligan; B S Ribner; J Z Montgomerie; M B Goetz; C G Mayhall; D Rimland
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 6.  Prevention of catheter-related bloodstream infection in patients on hemodialysis.

Authors:  Michiel G H Betjes
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

7.  Immediate and long-term efficacy of systemic antibiotics for eradicating nasal colonization with Staphylococcus aureus.

Authors:  B A Lipsky; R E Pecoraro; J H Ahroni; R L Peugeot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

8.  Variation and persistence of methicillin-resistant Staphylococcus aureus strains among individual patients over extended periods of time.

Authors:  J N Maslow; S Brecher; J Gunn; A Durbin; M A Barlow; R D Arbeit
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

9.  Staphylococcus aureus septic arthritis in patients on hemodialysis treatment.

Authors:  S Slaughter; R J Dworkin; D N Gilbert; J E Leggett; S Jones; R Bryant; M A Martin
Journal:  West J Med       Date:  1995-08

10.  Association between Staphylococcus aureus nasopharyngeal colonization and septicemia in patients infected with the human immunodeficiency virus.

Authors:  T Weinke; R Schiller; F J Fehrenbach; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.